Excessive IL-1ß production and IL-1 signalling as a consequence of inflammasome assembly and activation upon NLRP3 stimulation in CAPS spectrum represents an exemplar of targetted-therapeutic approach based on selective cytokine blockade to control inflammation (11). The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.